← Back to Search

Epilepsy Visit Planner for Epilepsy

N/A
Recruiting
Led By Chloe Hill, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after baseline visit
Awards & highlights
No Placebo-Only Group

Summary

This trial assesses whether a tablet-based tool can help improve patient-provider communication & quality of life for those with epilepsy.

Who is the study for?
This trial is for adults with drug-resistant epilepsy who are being treated at the University of Michigan's Epilepsy clinics. Participants must be able to complete study questionnaires in English and not have cognitive impairments that would prevent this.
What is being tested?
The trial is testing a tablet-based tool called the 'Epilepsy Visit Planner' to see if it improves patient-provider communication and quality of life for epilepsy patients, compared to those who don't use the tool.
What are the potential side effects?
Since this trial involves using a planning tool rather than medication, there are no direct medical side effects. However, participants may experience stress or frustration if they find the technology difficult to use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after baseline visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after baseline visit for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Perceived Efficacy in Patient-Physician Interactions Questionnaire (PEPPI), difference in mean score between trial arms
Secondary study objectives
Acceptability of Intervention Measure, assessed in intervention arm
Feasibility, assessed in intervention arm
Perceived Involvement in Care (PICS), difference in mean score between trial arms
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Standard care arm - patient participantsExperimental Treatment1 Intervention
This group will be enrolled first.
Group II: Intervention arm (Epilepsy Visit Planner) - provider participantsExperimental Treatment1 Intervention
Epilepsy providers will be recruited from the University of Michigan (approximately 10 providers).
Group III: Intervention arm (Epilepsy Visit Planner) - patient participantsExperimental Treatment2 Interventions
This group will be enrolled after the standard care arm enrollment is completed.

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,854 Previous Clinical Trials
6,433,399 Total Patients Enrolled
3 Trials studying Epilepsy
497 Patients Enrolled for Epilepsy
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,377 Previous Clinical Trials
651,654 Total Patients Enrolled
79 Trials studying Epilepsy
25,401 Patients Enrolled for Epilepsy
Chloe Hill, MDPrincipal InvestigatorUniversity of Michigan

Media Library

Standard care arm - patient participants Clinical Trial Eligibility Overview. Trial Name: NCT05928598 — N/A
Epilepsy Research Study Groups: Standard care arm - patient participants, Intervention arm (Epilepsy Visit Planner) - patient participants, Intervention arm (Epilepsy Visit Planner) - provider participants
Epilepsy Clinical Trial 2023: Standard care arm - patient participants Highlights & Side Effects. Trial Name: NCT05928598 — N/A
Standard care arm - patient participants 2023 Treatment Timeline for Medical Study. Trial Name: NCT05928598 — N/A
~97 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top